Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC

October 26th 2020

The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.

New Predictive Test Gains Momentum With 2 Positive Studies in Localized Colon Cancer

October 26th 2020

Immunoscore®, a host immune response classification tool, has demonstrated the ability to significantly affect treatment decision-making for patients with stage II colon cancer, particularly among those with high-risk disease.

AI-Powered Clinical Trial Tool Connects Young, Underserved Patients With CRC to Treatments and Research

October 24th 2020

The artificial intelligence–powered platform Clinical Trial Finder, which stemmed from a collaboration between the Colorectal Cancer Alliance and the digital health company TrialJectory, could prove beneficial for younger patients with colorectal cancer and for those who are being treated at community cancer centers.

Dr. Ahn on the Evolution of Targetable Alterations in CRC

October 23rd 2020

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC

October 22nd 2020

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRC

October 21st 2020

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.

Dr. Azad on Future Research Efforts in CRC

October 21st 2020

Nilofer Saba Azad, MD, discusses future research efforts in colorectal cancer.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Azad on the Importance of Germline Testing in CRC

October 19th 2020

Nilofer Saba Azad, MD, discusses the significance of germline testing in colorectal cancer.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRC

October 16th 2020

Nilofer Saba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Dr. Marshall on Challenges With Sequencing in CRC

October 15th 2020

John L. Marshall, MD, discusses sequencing challenges in colorectal cancer.

Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

October 15th 2020

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Dr. Azad on Remaining Challenges in CRC

October 15th 2020

Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.

Dr. Kopetz on the Design of the BEACON CRC Trial in BRAF V600E-Mutant mCRC

October 15th 2020

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Dr. Bekaii-Saab on the Emergence of Targeted Therapy in CRC

October 14th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.

Dr. Chu on the Importance of Identifying MSI Status in mCRC

October 14th 2020

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Dr. Farrington on the Importance of Genetic Testing in CRC

October 13th 2020

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutated mCRC

October 5th 2020

The combination of onvansertib plus with 5-fluorouracil, FOLFIRI, and bevacizumab was shown to have preliminary efficacy with acceptable safety when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Stoffel Underscores Importance of Germline Testing for Lynch Syndrome

October 2nd 2020

Elena M. Stoffel, MD, MPH, discusses the importance of genetic testing in detecting Lynch syndrome and other hereditary syndromes associated with risk of colorectal cancer and other diseases.